Fig. 3From: Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept studyBAFF levels before and after rituximab. BAFF level increased in almost all subjects after Rituximab (8/9). Subjects with poor B cell depletion (CJ:KREC ≥ 2.5) after therapy had only minor increases in serum BAFF level, compared to those with effective B cell depletionBack to article page